What We're Reading: Page 334
Industry reads hand-picked by our editors
May 31, 2016
-
Reuters
Roche and Novartis face off in biosimilar drug battle
-
Chicago Tribune
Shareholders approve $32 billion Baxalta-Shire merger
-
New York Times
Emmanuelle Charpentier's Still-Busy Life After Crispr
-
Wall Street Journal
FDA Asks Teva for More Information on Huntington’s Drug
May 27, 2016
May 26, 2016
-
Bloomberg
Celgene, Gilead Said to Join Suitors Mulling Medivation Bids
-
New York Times
Could Alzheimer's Stem From Infections? It Makes Sense, Experts Say
-
BioCentury
Sen. Alexander opposes FDA funding surge
-
International Business Times
Healthcare And Pharma CEOs Paid More Than Top Execs In Any Other Industry, Analysis Finds
May 25, 2016
-
Wall Street Journal
SEC Reviewed Valeant’s Use of ‘Non-GAAP’ Financial Measures
-
Reuters
Lilly says new type of pain drug could lessen need for opioids
-
Economic Times
Delhi High Court asks Roche to explain lawsuit over Avastin copy
-
Stat
There’s just one female CEO among San Diego’s public biotechs. Here’s why
May 24, 2016
-
Regulatory Focus
Republican Senators Lobby FDA Ahead of Decision on Sarepta’s DMD Drug
-
Reuters
UCB faces U.S. patent challenge for epilepsy drug
-
In the Pipeline
Trouble at Santa Cruz Biotechnology
-
San Francisco Business Journal
Another Genentech? These are the most likely companies
May 23, 2016
-
Triangle Business Journal
BioPharma Index: CEOs less confident in deal-making environment
-
Quartz
It’s a ‘psychedelic renaissance,’ as scientists identify medicinal qualities of hardcore drugs
-
The Associated Press
France to tighten up drug trial rules after fatal incident
-
PharmExec.com
Biopharma supports nearly 45 million US jobs, says report
Previous
